Superoxide Dismutase 1 Pathway In Amyotrophic Lateral Sclerosis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mutations in the SOD1 gene (Superoxide Dismutase 1) were the first genetic cause identified in familial amyotrophic lateral sclerosis (ALS), accounting for approximately 12-20% of familial ALS cases 1. Over 190 SOD1 mutations have been identified, providing critical insights into ALS pathogenesis through the study of toxic gain-of-function mechanisms.
SOD1 is a 32 kDa metalloenzyme that catalyzes the dismutation of superoxide radical (O₂⁻) to hydrogen peroxide (H₂O₂) and molecular oxygen 2:
2 O₂⁻ + 2 H⁺ → H₂O₂ + O₂
This reaction protects cells from oxidative damage caused by reactive oxygen species (ROS).
SOD1 consists of:
- β-barrel fold: 8 antiparallel β-strands
- Metal binding sites: One Zn²⁺ (structural) + One Cu²⁺ (catalytic)
- Disulfide bond: Cys57-Cys146 (intramolecular)
- Dimer interface: Homodimer formation
- Cytosol (predominant)
- Mitochondrial intermembrane space (partial)
- Nucleus (minor)
| Mutation |
Location |
Frequency |
Phenotype |
| A4V |
N-terminus |
~50% (US) |
Aggressive, rapid progression |
| G93A |
β-strand 4 |
Common |
Moderate progression |
| G37R |
β-strand 2 |
Common |
Intermediate |
| H46R |
Loop 4 |
Asian populations |
Slow progression |
| L126Z |
C-terminus |
Rare |
Unknown |
Mutations affect:
- Metal binding affinity (Cu/Zn)
- Dimer stability
- Disulfide bond integrity
- Proteolytic resistance
SOD1 mutations cause disease through loss of dismutase activity-independent mechanisms 3:
Wild-type SOD1 → Normal dismutase → Cellular protection
↓
Mutant SOD1 → Toxic gain-of-function → Multiple pathogenic pathways
Mutant SOD1 forms toxic aggregates through multiple mechanisms 4:
- Increased aggregation propensity: Mutant proteins misfold
- Impaired chaperone clearance: Hsp70, Hsp90 overwhelmed
- Proteasome dysfunction: Accumulation of misfolded proteins
- Inclusion body formation: Aggresomes and aggregates
flowchart TD
A[SOD1 Mutation] --> B[Protein misfolding] -->
B --> C[Increased aggregation propensity] -->
C --> D[Impaired chaperone function] -->
C --> E[Proteasome dysfunction] -->
D --> F[Aggregation] -->
E --> F
F --> G[Aggresome formation] -->
G --> H[Cytotoxic inclusions] -->
B --> I[Loss of dimer stability] -->
I --> J[Monomer accumulation] -->
J --> F
B --> K[Disulfide bond reduction] -->
K --> L[Highly reactive Cys residues] -->
L --> M[Abnormal disulfide cross-linking] -->
M --> F
H --> N[Motor neuron death]
SOD1 mutants cause mitochondrial damage through 5:
- Import interference: Disrupted mitochondrial protein import
- Respiratory chain defects: Complex I and IV dysfunction
- ROS overproduction: Paradoxical increase in oxidative stress
- Apoptosis activation: Cytochrome c release
Motor neurons have long axons requiring efficient transport:
- Mutant SOD1 disrupts microtubule-based transport
- Impaired vesicle trafficking
- Reduced neurotrophic factor delivery
- Synaptic dysfunction
Non-cell autonomous toxicity in ALS 6:
- Astrocytes: Impaired glutamate uptake (EAAT2 loss)
- Microglia: Chronic activation, pro-inflammatory cytokine release
- Oligodendrocytes: Demyelination, metabolic support failure
Mutant SOD1 accumulation in the ER triggers:
Motor neurons are selectively vulnerable due to:
- Large cell size: High protein synthesis burden
- Long axons: Extreme transport requirements
- High metabolic demand: High ROS production
- Calcium dysregulation: Excitotoxicity susceptibility
- Unique RNA processing: Specialized transport granules
| Factor |
Contribution |
| Size |
Protein homeostasis burden |
| Axon length |
Transport dependence |
| Calcium handling |
Excitotoxicity |
| Mitochondria |
Energy demand |
| Neurotrophin dependency |
Support dependence |
| Approach |
Mechanism |
Status |
| Antisense oligonucleotides |
Knockdown SOD1 |
Phase 3 (BIIB067) |
| CRISPR gene editing |
Correct mutations |
Preclinical |
| RNAi |
Silence mutant expression |
Preclinical |
| Target |
Compound |
Mechanism |
| Aggregation |
Arimoclomol |
Hsp90 co-inducer |
| Oxidative stress |
Edaravone |
ROS scavenger |
| Glutamate |
Riluzole |
Anti-excitotoxic |
| Mitochondria |
Olesoxime |
Mitochondrial stabilizer |
- Autophagy enhancers: Rapamycin, trehalose
- Proteasome modulators: Bortezomib (caution)
- Hsp90 inhibitors: Geldanamycin derivatives
- Disaggregation: Hsp104 modulators
¶ Biomarkers and Clinical Trials
- Neurofilament light chain (NfL): Serum/CSF
- Neurofilament phosphorylated heavy chain (pNfH): CSF
- Mutant SOD1: Specific detection in CSF
| Trial |
Compound |
Outcome |
| NCT02623699 |
BIIB067 (tofersen) |
Primary endpoint missed, but showed benefits |
| NCT00706147 |
Arimoclomol |
Failed Phase 2/3 |
| NCT01908791 |
Edaravone |
Approved (IV formulation) |
- diseases/als: Amyotrophic Lateral Sclerosis
- genes/sod1: SOD1 gene page
- proteins/sod1-protein: SOD1 protein
- mechanisms/mitochondrial-dysfunction-als: Mitochondrial dysfunction
- mechanisms/protein-aggregation-neurodegeneration: Protein aggregation
- entities/mitochondria: Mitochondrial biology
- treatments/als-drug-pipeline: ALS drug development
The study of Superoxide Dismutase 1 Pathway In Amyotrophic Lateral Sclerosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Rosen DR, et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 364(6435):362. PMID:8332197
- Valentine JS, et al. (2005). Superoxide dismutase and ALS. Proc Natl Acad Sci. 102(21):7557-7562. PMID:15923139
- Boillee S, et al. (2006). ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 52(1):39-59. PMID:17015226
- Durazo A, et al. (2021). Mutant SOD1 aggregation in ALS. J Mol Biol. 433(1):166923. PMID:33577894
- Pickles S, et al. (2018). Mitochondrial dysfunction in ALS. Brain Pathol. 28(5):769-779. PMID:29660743
- Ilieva H, et al. (2009). Non-cell autonomous toxicity in ALS. J Cell Biol. 187(6):761-772. PMID:19948480
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
6 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 26%